Cargando…
Breast Cancer Screening and Axillary Adenopathy in the Era of COVID-19 Vaccination
A 50-year-old woman with persistent axillary lymphadenopathy 17 weeks after COVID-19 vaccination was ultimately diagnosed with biopsy-proven benign reactive lymphadenopathy. In contrast, a 60-year-old woman with axillary lymphadenopathy and concurrent suspicious breast findings 9 weeks after COVID-1...
Autores principales: | Wolfson, Stacey, Kim, Eric |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Radiological Society of North America
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9580051/ https://www.ncbi.nlm.nih.gov/pubmed/36219117 http://dx.doi.org/10.1148/radiol.222040 |
Ejemplares similares
-
Axillary Adenopathy after COVID-19 Vaccine: No Reason to Delay
Screening Mammogram
por: Wolfson, Stacey, et al.
Publicado: (2022) -
Axillary Adenopathy after COVID-19 Vaccine: No Reason to Delay
Screening Mammogram
por: Wolfson, Stacey, et al.
Publicado: (2022) -
Incidence of Axillary Adenopathy in Breast Imaging After COVID-19 Vaccination
por: Robinson, Kristin A., et al.
Publicado: (2021) -
Unilateral axillary Adenopathy in the setting of COVID-19 vaccine
por: Mehta, Nishi, et al.
Publicado: (2021) -
Axillary adenopathy after COVID-19 vaccine in patients undergoing breast ultrasound
por: Giorgis, Sara De, et al.
Publicado: (2021)